Oxytocin Or Derivative Patents (Class 514/11.6)
  • Patent number: 10967040
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 6, 2021
    Assignee: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • Patent number: 10010575
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: July 3, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 9981006
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 29, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 9974827
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 22, 2018
    Assignee: Par Pharmaceutical, Inc.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 9962422
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: May 8, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Patent number: 9949923
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: April 24, 2018
    Assignee: OptiNose AS
    Inventor: Per Gisle Djupesland
  • Patent number: 9434767
    Abstract: The present invention provides a method for preparing atosiban acetate. The method comprises the following steps of: synthesizing to obtain linear atosiban; dissolving the linear atosiban in an acetonitrile aqueous solution, adjusting the pH value with ammonia water, adding H2O2 for oxidizing, filtering, purifying, and transferring salt to obtain the atosiban acetate. In the present invention, an appropriate route is provided, the linear atosiban is synthesized by adopting a solid phase method, and the atosiban is obtained by liquid phase oxidation. The method has the advantages of capabilities of solving the problem of insolubility of the linear atosiban, reducing the reaction size to the maximum extent and shortening reaction time, and being high in yield and easy to industrialize.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: September 6, 2016
    Assignee: HYBIO PHARMACEUTICAL CO., LTD.
    Inventors: Qing Xiao, Jian Liu, Hongling Li, Yaping Ma, Jiancheng Yuan
  • Patent number: 9034821
    Abstract: The present invention relates to a novel pharmaceutical composition comprising oxytocin and/or one or more fragment(s) and/or variant(s) thereof and at least one non-ionic cellulose ether, such as hydroxypropylmethylcellulose, said pharmaceutical composition having a low pH. The present pharmaceutical composition has been shown to provide an exceptionally suitable environment for oxytocin, as the stability thereof has increased significantly as compared to previous compositions with this molecule. The pharmaceutical composition according to the invention can be used for medical purposes, such as in the treatment of climacteric disorders.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 19, 2015
    Inventors: Kerstin Uvnäs-Moberg, Anders Carlsson
  • Patent number: 9023793
    Abstract: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: May 5, 2015
    Assignee: Retrophin, Inc.
    Inventors: Alexis Kays Leonard, Joshua Orion Sestak, Henry R. Costantino, Anthony P. Sileno, Lalit Raj Peddakota, Kayvon Emile Sharghi, Garland M. Bellamy, Jason Philip Gesty, Steven C. Quay
  • Publication number: 20150099703
    Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Inventors: Gunvor Ekman-Ordeberg, Anders Malmström
  • Publication number: 20150057226
    Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment of labor arrest. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with an agent capable of promoting myometrial contractions of the uterus and thereby re-establish effective labor.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 26, 2015
    Inventors: Gunvor Ekman-Ordeberg, Anders Malmström
  • Publication number: 20150018275
    Abstract: This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy.
    Type: Application
    Filed: September 4, 2013
    Publication date: January 15, 2015
    Applicant: EMORY UNIVERSITY
    Inventors: Larry James Young, Meera E. Modi
  • Publication number: 20150004196
    Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
    Type: Application
    Filed: June 5, 2014
    Publication date: January 1, 2015
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 8853158
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: October 7, 2014
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Chu de Toulouse, Universite d'Aix-Marseille
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • Publication number: 20140294969
    Abstract: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.
    Type: Application
    Filed: November 7, 2011
    Publication date: October 2, 2014
    Applicant: Monash University
    Inventors: Michelle Mcintosh, David Morton, Tomas Sou, Livesey Olerile, Richard Prankerd
  • Publication number: 20140171369
    Abstract: The present invention relates to a novel pharmaceutical composition comprising oxytocin and/or one or more fragment(s) and/or variant(s) thereof and at least one non-ionic cellulose ether, such as hydroxypropylmethylcellulose, said pharmaceutical composition having a low pH. The present pharmaceutical composition has been shown to provide an exceptionally suitable environment for oxytocin, as the stability thereof has increased significantly as compared to previous compositions with this molecule. The pharmaceutical composition according to the invention can be used for medical purposes, such as in the treatment of climacteric disorders.
    Type: Application
    Filed: April 13, 2012
    Publication date: June 19, 2014
    Applicant: Pep-Tonic Medical AB
    Inventors: Kerstin Uvnäs Moberg, Anders Carlsson
  • Publication number: 20140141102
    Abstract: As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.
    Type: Application
    Filed: October 27, 2011
    Publication date: May 22, 2014
    Applicant: DIGNITY HEALTH
    Inventors: Robert E. Garfield, Shao-Qing Shi, Leili Shi
  • Publication number: 20140072531
    Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 13, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
  • Publication number: 20140018295
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 16, 2014
    Applicant: OPTINOSE AS
    Inventor: Per Gisle Djupesland
  • Publication number: 20130331319
    Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 12, 2013
    Inventors: Nicholas V. Perricone, Chim Potini
  • Publication number: 20130330380
    Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.
    Type: Application
    Filed: June 25, 2013
    Publication date: December 12, 2013
    Applicant: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 8557281
    Abstract: A pharmaceutical controlled release composition in solid dosage form is provided which comprises (I) a water-swell able linear polymer obtainable by reacting together: (a) a polyethylene oxide; (b) a C5 to C20 diol; and (c) a diisocyanate; and (II) a releasable pharmaceutically active agent.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: October 15, 2013
    Assignee: Ferring B.V.
    Inventors: Janet A. Halliday, Jukka Tuominen, Mark Livingstone, Frank Koppenhagen, Lilias Currie, Sarah Stewart
  • Publication number: 20130231279
    Abstract: The disclosure provides a method for enhancing memory of a subject, lowering blood glucose levels in a subject, and treating schizophrenia, the methods comprise intranasally administering to the subject an amount of a oxytocin peptide or analogue thereof having a beneficial effect.
    Type: Application
    Filed: July 30, 2011
    Publication date: September 5, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: David Feifel
  • Patent number: 8501691
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: August 6, 2013
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research & Education
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20130130985
    Abstract: Peptide analogues of oxytocin are described together with methods of treating conditions ameliorated by modulating oxytocin receptor. The peptide analogues are seleno or telluro peptide analogues. Methods of synthesis of selenocysteine, tellurocysteine and oxytocin analogues are also described.
    Type: Application
    Filed: May 24, 2010
    Publication date: May 23, 2013
    Inventors: Paul Alewood, Markus Muttenthaler, Zoltan Dekan
  • Patent number: 8445436
    Abstract: The invention discloses a pharmaceutical composition containing oxytocin and melatonin in amounts therapeutically effective for inducing labor in a pregnant human patient. Preferably, the oxytocin content is reduced to mitigate unwanted side effects and the melatonin content synergistically enhances the oxytocin's labor-inducing effectiveness. Also disclosed is a pharmaceutical composition for treatment of a pregnant human patient experiencing pre-term labor characterized by early expression of melatonin receptors in myometrial cells, the composition containing one or more agents which interfere with melatonin binding to said receptors.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: May 21, 2013
    Assignee: Florida State University Research Foundation, Inc.
    Inventor: James Olcese
  • Publication number: 20130085106
    Abstract: The invention provides a method of treating a psychiatric or medical disorder in a mammalian subject, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist (e.g., oxytocin). Optionally, the oxytocin receptor agonist is delivered by intranasal administration. Further provided is a method of increasing social cognition, increasing social functioning, increasing empathy, increasing trust of others, reducing paranoia and/or reducing hostility in a subject with a psychotic disorder, a mood disorder characterized by psychotic features, a personality disorder or a pervasive developmental disorder, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist.
    Type: Application
    Filed: May 19, 2011
    Publication date: April 4, 2013
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Cort A. Pedersen, Marla L. Boccia, Alexei Kampov-Polevoi
  • Publication number: 20130085100
    Abstract: The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin resistance and related methods and pharmaceutical formulations. In particular, the invention relates to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful in the treatment of metabolic syndrome.
    Type: Application
    Filed: May 17, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITÉ DE GENÈVE
    Inventors: Françoise Rohner-Jeanrenaud, Nicolas Deblon
  • Publication number: 20120322736
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Application
    Filed: May 24, 2012
    Publication date: December 20, 2012
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20120270785
    Abstract: The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking.
    Type: Application
    Filed: September 29, 2010
    Publication date: October 25, 2012
    Inventors: Iain Stewart McGregor, Dean Samuel Carson, Adam John Guastella, Michael Thomas Bowen
  • Publication number: 20120258176
    Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.
    Type: Application
    Filed: May 7, 2012
    Publication date: October 11, 2012
    Inventors: Hsing-Wen Sung, Zi-Xian Liao, Shu-Fen Peng, Hosheng Tu
  • Publication number: 20120244213
    Abstract: The present invention relates to methods of treating for treating stuttering or other speech impediments that are not related to psychiatric disorders or autism using oxytocin or its analogs.
    Type: Application
    Filed: December 14, 2010
    Publication date: September 27, 2012
    Inventor: Liora Emanuel
  • Publication number: 20120237476
    Abstract: The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: September 20, 2012
    Applicant: Foressee Pharmaceuticals, LLC
    Inventors: Yuhua LI, Benjamin CHIEN
  • Patent number: 8258096
    Abstract: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: September 4, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, William H. Frey, II, Daniel I. Jacobs, Martin S. Angst
  • Patent number: 8252745
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: August 28, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20120214733
    Abstract: The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered.
    Type: Application
    Filed: September 21, 2010
    Publication date: August 23, 2012
    Applicant: FERRING INTERNATIONAL CENTER S.A.
    Inventors: Kazimierz Wisniewski, Claudio Daniel Schteingart, Sudarkodi Alagarsamy, Robert Galyean
  • Patent number: 8222202
    Abstract: The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of, inter alia, conditions associated with critical care sepsis, septic shock, hepatorenal syndrome type I, hypertension induced by endstage venal disease, severe burns, thermal injury as well as to a method for treatment of the conditions by administering the compounds. The compounds used are represented by the general formula (1), as further defined in the specification.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: July 17, 2012
    Assignee: Ferring B.V.
    Inventors: Regent Laporte, Pierre J. M. Riviere
  • Publication number: 20120178686
    Abstract: The present invention describes a method of inducing lactation in non-human mammals by using a single administrations of an estrogen compound, a dopaminergic antagonist, and oxytocin. For example, the estrogen compound may be a long acting composition and is administered at least one week before the dopaminergic antagonist. However, the oxytocin administration may be given the day after the dopaminergic antagonist, after which lactation may begin immediately. Preferred compounds may comprise a non-17? estradiol and domperidone. Such an injection protocol has resulted in the production of commercially viable volumes of milk from transgenic pigs.
    Type: Application
    Filed: August 27, 2010
    Publication date: July 12, 2012
    Inventor: Jeffrey P. Erickson
  • Publication number: 20120172304
    Abstract: Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.
    Type: Application
    Filed: August 5, 2011
    Publication date: July 5, 2012
    Inventors: Alexis Kays LEONARD, Joshua Orion SESTAK, Henry R. COSTANTINO, Anthony P. SILENO, Lalit Raj PEDDAKOTA, Kayvon Emile SHARGHI, Garland M. BELLAMY, Jason Philip GESTY, Steven C. QUAY
  • Publication number: 20120164072
    Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.
    Type: Application
    Filed: May 4, 2010
    Publication date: June 28, 2012
    Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
  • Patent number: 8202838
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: June 19, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Patent number: 8198240
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: June 12, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Trigemina, Inc., HealthPartners Research Foundation
    Inventors: David C. Yeomans, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20120114561
    Abstract: Methods for treating neurodegenerative disorders, including Parkinson's disease, are provided. The methods comprise administrating a therapeutically effective amount of oxytocin or oxytocin analogs to alleviate one or more symptoms of Parkinson's disease. Methods for determining the effectiveness of oxytocin therapy by itself or in addition to one or more adjunctive therapies in alleviating one or more symptoms of Parkinson's disease are also discussed.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventor: Paul J. Zak
  • Publication number: 20120087891
    Abstract: The present invention relates biomedically useful compositions containing bioactive agents and biodegradable carbohydrate polyethers that exhibit reverse thermogelation properties in aqueous media. The microstructure structure and properties of the carbohydrate polyethers can be conveniently controlled with respect to functionality, molecular weight, polydispersity index, microstructure and tertiary structure, they can be customized for use in a variety of biomedical applications including drug delivery, cell delivery, surgical procedures and the like.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 12, 2012
    Inventor: Alexander A. Gorkovenko
  • Publication number: 20120076757
    Abstract: The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide.
    Type: Application
    Filed: November 22, 2011
    Publication date: March 29, 2012
    Applicant: Cephalon, Inc.
    Inventors: Steve L. Durfee, Gary Thurman
  • Publication number: 20120058938
    Abstract: The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body. In particular, the invention concerns the use of a nutritional composition for the treatment of a disorder, which is mediated by a postprandial endocrine or neurological response in a human body, wherein the nutritional composition comprises one or more of a specific protein fraction, a specific carbohydrate fraction and a specific nutritional fiber fraction.
    Type: Application
    Filed: March 9, 2010
    Publication date: March 8, 2012
    Applicant: N.V. NUTRICIA
    Inventors: Robert Johan Joseph Hageman, Mirian Lansink
  • Publication number: 20120058087
    Abstract: The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection.
    Type: Application
    Filed: December 18, 2009
    Publication date: March 8, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Morten Rønn Petersen, Anders Miki Bojesen
  • Publication number: 20120045430
    Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 23, 2012
    Inventors: Dan Luo, Yougen Li
  • Publication number: 20120028898
    Abstract: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.
    Type: Application
    Filed: October 7, 2011
    Publication date: February 2, 2012
    Inventors: David C. YEOMANS, Martin S. Angst, William H. Frey, II, Daniel I. Jacobs
  • Publication number: 20120009260
    Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.
    Type: Application
    Filed: June 10, 2011
    Publication date: January 12, 2012
    Inventors: Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos